BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Industry Taking Notice of Araris Biotech’s Linker Technology for ADC Delivery

  The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.

  July 21, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Money on the Move: July 14 – 21

  More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.

  July 21, 2021

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Policy

  Koselugo: The First Non-Surgical Alternative for Rare Plexiform Neurofibroma

  Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.

  July 21, 2021

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Genetown

  Novartis Delivers Strong Second Quarter and 50 Million CureVac Vaccines

  The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.

  July 21, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  J&J Highlight Massive Q2 Earnings While Covid Vaccine Doubts Grow and Legal Battles Rage

  As Johnson & Johnson touted $23.3 billion sales on its Q2 earnings call this morning, other news in the media hasn’t been as kind to the massive, global conglomerate.

  July 21, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Genetown

  Albireo Breaks New Ground with Approvals for First Drug Bylvay in PFIC

  It will immediately begin to sell Bylvay to treat patients impacted by PFIC, a rare cholestatic liver disease that often leads to cirrhosis and liver failure within the first ten years of life.

  July 21, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Biogen Ties Up with Mirimus for Neurological Indications, and Other Collaborations

  Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.

  July 21, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Genentech’s Combo Therapy for Rare Blood Cancers Scores Breakthrough Designation

  Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.

  July 21, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug

  The FDA placed a clinical hold on Magenta’s clinical program for acute myeloid leukemia and myelodysplastic syndrome, which made its shares drop nearly 7% this morning.

  July 21, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Study: Transplant From Mother’s Gut May Reverse Newborns’ Risk for Type 1 Diabetes

  Researchers say transplanting fecal microbiota from the mother into the newborn can reverse the risk for Type 1 diabetes for babies who had been exposed to antibiotic treatments early.

  July 21, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN